Matricelf Stock Price, News & Analysis
Company Description
Matricelf Ltd. (MTRLF) develops personalized regenerative medicine technologies for engineered neural tissue implants intended for spinal cord injury. The company is a biotechnology issuer whose public announcements identify its Tel Aviv Stock Exchange ticker as MTLF. Its operating focus is tissue engineering: using patient-specific biological material, stem-cell biology, and a proprietary human extracellular-matrix hydrogel platform to create three-dimensional neural tissue for potential implantation in damaged spinal cord tissue.
The company's lead application is a personalized spinal cord implant designed as an autologous therapy. Autologous approaches use a patient's own biological material, which Matricelf describes as a way to reduce the risk of implant rejection. The platform is also described as a broader method for personal three-dimensional printing of tissues and organs, although the company's current public development emphasis is on neural tissue for spinal cord injury.
Technology platform
Matricelf's technology combines neural tissue engineering with a hydrogel platform based on human extracellular matrix. Company announcements describe engineered neural tissues evaluated through cellular, genetic, protein-level, and functional measures, including neural marker expression and electrical activity. The company has reported safety characterization work using advanced RNA sequencing methods to examine the cellular composition of implant batches as part of its preclinical development program.
The technology originated from research associated with Tel Aviv University and was licensed to Matricelf under an exclusive global licensing agreement signed in 2019. Company materials also describe work connected to the Sagol Center for Regenerative Biotechnology at Tel Aviv University, including preclinical research involving engineered spinal cord tissues in chronic spinal cord injury models.
Development and manufacturing focus
Matricelf operates as a development-stage regenerative medicine company. Its recurring activities include preclinical safety and efficacy work, manufacturing process development, clinical-grade production planning, and collaboration with external research and technology organizations. The company has described a strategic collaboration with the CiRA Foundation in Japan to evaluate induced pluripotent stem cells in combination with Matricelf's proprietary neural tissue engineering platform. The stated objective of that work is to assess compatibility with automated, large-scale manufacturing approaches for engineered neural tissues.
Matricelf has also reported manufacturing-related research involving stem cells generated through artificial-intelligence-based technology in collaboration with Cellino Biotech. These activities fit the company's broader focus on translating personalized regenerative implants from laboratory-scale engineering into processes that could support regulated clinical development.
Corporate profile
Matricelf is based in Israel, and company announcements cite facilities in Ness Ziona. Its public communications center on regenerative medicine, spinal cord injury, personalized neural tissue implants, collaborations in stem-cell manufacturing, preclinical testing, and preparation for human clinical development. The company's profile is defined by its autologous tissue-engineering platform rather than by marketed pharmaceutical products or a diversified commercial portfolio.
Stock Performance
Latest News
Matricelf has 7 recent news articles. Key topics include partnership. View all MTRLF news →
SEC Filings
Financial Highlights
Upcoming Events
First clinical implantation target
First-in-human trials
Matricelf has 2 upcoming scheduled events. The next event, "First clinical implantation target", is scheduled for January 1, 2027 (in 201 days). Investors can track these dates to stay informed about potential catalysts that may affect the MTRLF stock price.
Short Interest History
Short interest in Matricelf (MTRLF) currently stands at 5.0 thousand shares, up 1000.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 6310.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Matricelf (MTRLF) currently stands at 1.0 days, down 53.1% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.1 days.
MTRLF Company Profile & Sector Positioning
Matricelf (MTRLF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing MTRLF often look at related companies in the same sector, including Kadimastem (KMSTF), GEMINA LABORATORIES LTD (GLABF), Thiogenesis (TTIPF), Harvard Apparatus Regenerative Technology Inc. (HRGN), and Provectus Biopha (PVCT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MTRLF's relative position within its industry.